2016
Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients
Borges T, O'Malley J, Wo L, Murakami N, Smith B, Azzi J, Tripathi S, Lane J, Bueno E, Clark R, Tullius S, Chandraker A, Lian C, Murphy G, Strom T, Pomahac B, Najafian N, Riella L. Codominant Role of Interferon‐γ– and Interleukin‐17–Producing T Cells During Rejection in Full Facial Transplant Recipients. American Journal Of Transplantation 2016, 16: 2158-2171. PMID: 26749226, PMCID: PMC4979599, DOI: 10.1111/ajt.13705.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibody developmentDe novo donor-specific antibodiesInterleukin-17-producing T cellsT helper 2 cell phenotypeFacial transplantationDonor-specific antibody developmentNovo donor-specific antibodiesChemotactic protein-1 levelsPeripheral blood mononuclear cellsAcute cellular rejectionAnti-HLA antibodiesDonor-specific antibodiesFollicular helper cellsImmune cell subsetsProtein-1 levelsBlood mononuclear cellsMedium-term outcomesSkin biopsy specimensFull facial transplantationCellular rejection processLife-changing procedureCellular rejectionCodominant roleDonor alloreactivityTransplant recipients
2014
The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant
Chandraker A, Arscott R, Murphy G, Lian C, Bueno E, Marty F, Rennke H, Milford E, Tullius S, Pomahac B. The Management of Antibody-Mediated Rejection in the First Presensitized Recipient of a Full-Face Allotransplant. American Journal Of Transplantation 2014, 14: 1446-1452. PMID: 24797454, DOI: 10.1111/ajt.12715.Peer-Reviewed Original ResearchConceptsAntibody-mediated rejectionPostoperative day 5Management of AMRDonor-specific antibody titersSubsequent antibody-mediated rejectionGrade III rejectionStandard induction regimenAnti-HLA antibodiesExtensive chemical burnsComposite tissue allotransplantationFull face transplantationMechanism of actionPreoperative crossmatchPresensitized recipientsSensitized recipientsDSA levelsInduction regimenC4d depositsPositive donorsBanff classificationAntibody titersCombination therapyPoor functionHistological signsClinical signs